Optimism in Takeda's R&D Transformation

Valentine’s Day represents a perfect opportunity to highlight news and updates from across biopharma that have hearts all aflutter.

In this week’s episode of “The Top Line,” we do just that, fueled by heart puns and holiday candy. Fierce’s Gabrielle Masson and Andrea Park discuss a new heart-focused biotech that recently emerged with $300 million and a cardiovascular drug that’s been named one of the most anticipated launches of 2025, as well as several other stories they’ve loved covering this year. 

To learn more about the topics in this episode:  

• Kardigan launches with cozy $300M series A and collection of late-stage cardio assets 

• Top 10 most anticipated drug launches of 2025  

• Cumberland's Duchenne drug improves blood flow from heart in phase 2 trial 

• Novartis' first Super Bowl ad aims to 'create a movement' with breast cancer awareness blitz 

• Don't call it a comeback: Pfizer returns to Super Bowl with ad pledging to 'knock out' cancer

• Takeda tightens reins on early-stage investments, looks to expand option deals: R&D head  

See omnystudio.com/listener for privacy information.